Abattis Bioceuticals Profit Margin

Abattis Bioceuticals (ATTBF) currently reports a profit margin of -852.4% as of September 2019. That compares with -931940.11% in the prior-year period — up 99.9% year over year. That is below the Healthcare sector average of 14.41%. Use the charts on this page to explore Abattis Bioceuticals's profit margin history and peer comparisons.

Abattis Bioceuticals's profit margin increased from -931940.11% to -852.4% — a 99.9% year-over-year increase (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abattis Bioceuticals's profit margin of -852.4% is lower than the Healthcare sector average of 14.41%. That is roughly 6013.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Abattis Bioceuticals's current -852.4% should be judged against Healthcare norms (sector average: 14.41%) and against ATTBF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -852.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for Abattis Bioceuticals, and consider following ATTBF for alerts when major investors trade the stock.